Matthew A. Cooper
Gründer bei Inflazome Ltd.
Aktive Positionen von Matthew A. Cooper
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Direktor/Vorstandsmitglied | 01.01.2016 | - |
| Vorstandsvorsitzender | 01.01.2016 | - | |
| Gründer | 01.01.2016 | - | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 20.07.2022 | - |
Karriereverlauf von Matthew A. Cooper
Ehemalige bekannte Positionen von Matthew A. Cooper
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Akubio Ltd.
 Akubio Ltd. Electronic Equipment/InstrumentsElectronic Technology Akubio Ltd. develops acoustic biosensor instruments. Its products are used in protein research and drug development. The company's technology based on quartz resonators delivers molecular identification and measurement of interactions in complex samples. Akubio was founded by Matthew A. Cooper in August 2001 and is headquartered in Cambridge, UK | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2001 | 31.05.2010 |
| Gründer | 01.08.2001 | 31.05.2010 | |
| University of Cambridge | Corporate Officer/Principal | - | - |
Ausbildung von Matthew A. Cooper
| University of Adelaide | Doctorate Degree |
Statistik
International
| Vereinigtes Königreich | 3 |
| Australien | 2 |
| Niederlande | 2 |
Operativ
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Electronic Technology | 2 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Akubio Ltd.
Akubio Ltd. Electronic Equipment/InstrumentsElectronic Technology Akubio Ltd. develops acoustic biosensor instruments. Its products are used in protein research and drug development. The company's technology based on quartz resonators delivers molecular identification and measurement of interactions in complex samples. Akubio was founded by Matthew A. Cooper in August 2001 and is headquartered in Cambridge, UK | Electronic Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Health Technology |
- Börse
- Insiders
- Matthew A. Cooper
- Erfahrung
